Teacher Retirement System of Texas Acquires 10,218 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Teacher Retirement System of Texas lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 18.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 65,927 shares of the biopharmaceutical company’s stock after acquiring an additional 10,218 shares during the quarter. Teacher Retirement System of Texas’ holdings in Amicus Therapeutics were worth $621,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of FOLD. Point72 Asia Singapore Pte. Ltd. bought a new stake in Amicus Therapeutics during the 3rd quarter valued at $55,000. R Squared Ltd purchased a new stake in shares of Amicus Therapeutics during the 4th quarter worth $79,000. KBC Group NV boosted its position in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Stephens Inc. AR purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $101,000. Finally, AlphaQuest LLC raised its holdings in Amicus Therapeutics by 635.1% in the fourth quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 9,272 shares in the last quarter.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $8.43 on Monday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a 50-day moving average of $9.28 and a two-hundred day moving average of $9.95. The stock has a market cap of $2.59 billion, a P/E ratio of -46.83, a P/E/G ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a one year low of $8.36 and a one year high of $12.65.

Analyst Ratings Changes

FOLD has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.